GSK Bio
NEWS
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
The two antibody candidates, AL001 and AL101, are seen as potential first-in-class medications aimed at a range of neurodegenerative diseases.
The board strongly believes that Walmsley is the correct leader for the pharmaceutical business arm of GSK, which is being referred to as New GSK.
With business taking him throughout North and South America, Asia, and Europe, he’s learned to adapt and appreciate the nuances of a multicultural environment.
Elliott said the GSK has underperformed for more than a decade and called for the board to select leaders who have significant background and experience in biopharma and health care.
CEO Emma Walmsley’s vision includes a projected $46 billion in annual sales from the stand-alone pharma company by 2031 and more than 10% operating profit over the next five years.
GSK CEO Emma Walmsley may face some contentious opposition from key investors interested in forcing a management change following the planned investor update.
Shares of iTeos Therapeutics skyrocketed more than 50% in premarket trading after it struck an agreement with GSM to co-develop and commercialize a cancer treatment.
AbbVie has been the target of multiple legal inquiries and challenges of its pricing and patent protections. Now, a U.S. senator is taking a gander at the company’s taxes.
JOBS
IN THE PRESS